SCHEMBL30859481

SCHEMBL30859481

CC(C)(C)[Si](C)(C)OCCCc1ccc(Cl)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DUT P33316 1/20 0.40
KCNH2 Q12809 5/20 0.40
SLC6A2 P23975 3/20 0.40
HRH1 P35367 3/20 0.40
HRH3 Q9Y5N1 2/20 0.40
SLC6A4 P31645 2/20 0.40
SLC6A3 Q01959 2/20 0.40
CHRM2 P08172 1/20 0.40
ADRA2C P18825 1/20 0.40
CACNA1C Q13936 1/20 0.40
SCN5A Q14524 1/20 0.40
CHRM4 P08173 1/20 0.39
HTR2C P28335 1/20 0.39
HTR7 P34969 1/20 0.39
TMEM97 Q5BJF2 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
TAAR1 Q96RJ0 2/20 0.38
HTR2A P28223 1/20 0.38
HTR2B P41595 1/20 0.38
CHRNA4 P43681 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14183641 0.85 KCNH2 (0.42) DUTKCNH2HRH1TAAR1IGF1R
SCHEMBL14832628 0.83 MAOB (0.43) DUTHTR2AIDO1ALDH1A1
SCHEMBL662532 0.83 DUT (0.40) DUTIDO1ALDH1A1CYP3A4
SCHEMBL662026 0.83 DUT (0.40) DUTKCNH2IDO1
SCHEMBL410888 0.83 DUT (0.40) DUTSIGMAR1TAAR1HTR2AIDO1
SCHEMBL2252126 0.83 IDO1 (0.53) DUTIDO1L3MBTL1
SCHEMBL7003015 0.81 TAAR1 (0.44) CHRM2TAAR1IDO1AGXTCYP3A4
SCHEMBL31558448 0.81 DUT (0.39) DUTSLC6A2SLC6A4SLC6A3IDO1
SCHEMBL1629726 0.80 IGF1R (0.41) DUTKCNH2HRH1TAAR1IGF1R
SCHEMBL664372 0.80 ALDH1A1 (0.42) DUTIDO1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250223307-A1 MDM2/MDMX DOUBLE-TARGET INHIBITOR COMPOUND, PRODRUG, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF GLOBAL HEALTH DRUG DISCOVERY INSTITUTE (CN) 2025-07-10 US disclosed
EP-4582420-A1 MDM2/MDMX DOUBLE-TARGET INHIBITOR COMPOUND, PRODRUG, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF Global Health Drug Discovery Institute (CN) 2025-07-09 EP disclosed
WO-2024104304-A1 MDM2/MDMX DOUBLE-TARGET INHIBITOR COMPOUND, PRODRUG, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF 北京华益健康药物研究中心 2024-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250223307-A1 MDM2/MDMX DOUBLE-TARGET INHIBITOR COMPOUND, PRODRUG, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF MDM2, TP53, TP53BP1 DUT 1505/4885KCNH2 4875/4885SLC6A2 4594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.